Showing results (221-230 of 228) with videos related to
Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 228 results.
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.Blood Advances|January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN StudyKrish Patel, Julie M Vose, Sunita D Nasta, et al.Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.The New England Journal of Medicine|July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, et al.The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.Blood|July 21, 2020
Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R Mato, Lindsey E Roeker, Nicole Lamanna, et al.Pageof 23